Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.
Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, Neil Dear T, Van Valckenborgh E, Baldock PA, Rogers MJ, Eaton CL, Vanderkerken K, Pettit AR, Quinn JM, Zannettino AC, Phan TG, Croucher PI. · 2015
Read Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. by Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, Neil Dear T, Van Valckenborgh E, Baldock PA, Rogers MJ, Eaton CL, Vanderkerken K, Pettit AR, Quinn JM, Zannettino AC, Phan TG, Croucher PI. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4686867.txt.
Introduction
Michelle A. Lawson, Michelle M. McDonald, Natasa Kovacic, and a large team tracked dormant myeloma cells in Nature Communications in 2015. Multiple myeloma often returns after treatment, and doctors suspect sleeping cancer cells hidden in bone. Using live imaging in mice, the team watched single myeloma cells settle in the bone-lining niche, switch off, and later wake to form colonies. They asked which bone cells control the switch.
Contact with bone-lining cells or bone-building cells turned dormancy on. Bone-eating cells, the osteoclasts, turned it off by remodeling the niche. Sleeping cells also shrugged off chemotherapy aimed at dividing cells, which fits the pattern of relapse. The work shows relapse may be fought from outside the cancer cell, by guarding the niche. That opens a treatment angle beside drugs that attack the tumor itself.
Catalog record
| CREATOR | Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, Neil Dear T, Van Valckenborgh E, Baldock PA, Rogers MJ, Eaton CL, Vanderkerken K, Pettit AR, Quinn JM, Zannettino AC, Phan TG, Croucher PI. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 73 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche By Michelle A Lawson, Michelle M McDonald, Natasa Kovacic, Weng Hua Khoo, Rachael L Terry, Jenny Down, Warren Kaplan, Julia Paton-Hough, Clair Fellows, Jessica A Pettitt, T Neil Dear, Els Van Valckenborgh Published in: Nature Communications DOI: 10.1038/ncomms9983 ABSTRACT Abstract Multiple myeloma is largely incurable, despite development of therapies that target myeloma cell-intrinsic pathways. Disease relapse is thought to originate from dormant myeloma cells, localized in specialized niches, which resist therapy and repopulate the tumour. However, little is known about the niche, and how it exerts cell-extrinsic control over myeloma cell dormancy and reactivation. In this study, we track individual myeloma cells by intravital imaging as they colonize the endosteal niche, enter a dormant state and subsequently become activated to form colonies. We demonstrate that dormancy is a reversible state that is switched ‘on' by engagement with bone-lining cells or osteoblasts, and switched ‘off' by osteoclasts remodelling the endosteal niche. Dormant myeloma cells are resistant to chemotherapy that targets dividing cells. The demonstration that the endosteal niche is pivotal in controlling myeloma cell dormancy highlights the potential for targeting cell-extrinsic mechanisms to overcome cell-intrinsic drug resistance and prevent disease relapse. Cancer cell dormancy is a poorly understood and often neglected stage in the evolution of many cancers, where extrinsic signals from the tumour microenvironment suppress active growth and proliferation, until more favourable conditions arise1,2. This is a major clinical problem, as dormant cancer cells may disseminate at an early stage in the disease3, become resistant to conventional therapies that target dividing cells1 and persist as minimal residual disease (MRD), which can be reactivated to promote disease relapse long after treatment cessation4. In the skeleton, dormant cells may co-exist in equilibrium with the bone microenvironment for years before reactivation and clinical relapse. In this regard, multiple myeloma, a primary haematological malignancy arising in bone, exemplifies the major therapeutic challenges posed by cancer cell dormancy. While novel therapies that selectively target cell ‘intrinsic' cancer properties have improved survival5, patients continue to relapse and myeloma remains largely incurable. Hence, understanding the ‘extrinsic' environmental factors that regulate myeloma cell dormancy is required to deliver complementary treatment strategies to overcome drug resistance and achieve complete remission and cure. Recently, whole-genome sequencing has identified key driver mutations and complex mutation patterns during the natural history of myeloma within individual patients6. These longitudinal analyses have revealed marked intra-clonal heterogeneity and shifting clonal dominance during disease progression and in response to drug treatments7,8,9. The ‘waxing and waning' of different myeloma clones (clonal tides) suggests that cancer cell growth and proliferation are not fixed genetic programmes8,9 that follow a linear model, but rather a branching and parallel, ‘Darwinian', model of clonal evolution that is subject to external selective pressures6,10. These data suggest that myeloma cell clones are able to reversibly switch ‘on' or ‘off' depending on the presence of favourable or unfavourable environmental signals. A critical component of this tumour microenvironment is the bone niche where myeloma cells initially colonize and are believed to reside11. However, the nature of this niche and mechanisms that control myeloma cell occupancy are poorly defined. Haematopoietic stem cells (HSCs) have long been known to occupy unique niches within the bone marrow microenvironment and this controls HSC dormancy, self-renewal and mobilization. These specialized microenvironments contain cells of the osteogenic lineage, perivascular cells and/or endothelial cells, and remodelling of these niches by osteoclasts regulates niche occupancy12,13,14,15,16,17,18. More recently, leukaemic cells and other cancer cells, including prostate cancer cells, have been shown to engraft in the HSC niche19,20,21. However, despite the importance of the niche in controlling tumour cell engraftment, the dynamic interactions between colonizing cancer cells and components of these specialized niches, and the impact of these interactions on the long-term fate of these cells, is poorly understood. Studying the dynamic interactions between dormant myeloma cells and the bone niche is particularly challenging, because it requires high-resolution deep-tissue imaging through intact bone in a live animal. Nevertheless, intravital microscopy of the bone marrow space beneath the bregma in the calvarium22 has been successfully used to study haematopoiesis23 and the HSC niche24,25,26,27, and has recently been applied to study the colonization of bone by leukaemic and myeloma cells20,28. However, to date, non-destructive microscopic imaging over periods of weeks to months is yet to be performed to longitudinally track the fate of the same individual myeloma cells as they become activated and escape dormancy. This would be a significant advance on longitudinal imaging by bioluminescence, which lacks the image resolution and potential for simultaneous visualization of the cells and structures that make up the bone niche. Furthermore, it would have distinct advantages over cross-sectional intravital microscopy, which may not capture the heterogeneity within and between different animals. Nevertheless, to image dormant myeloma cells in vivo, a robust method is required to discriminate resting from actively dividing cancer cells. Intravital dyes such as carboxyfluorescein succinimidyl ester, which label intracellular proteins, have relatively short half-lives and are unsuitable for the study of long-term cancer cell dormancy. Fluorescent stem cell markers have been used to track HSCs and study the epithelial stem cell niche, but these reporters may lack specificity when used in isolation29,30,31,32. To address this, here we have developed a method for dynamic longitudinal imaging of dormant myeloma cells within intact long bones of mice using intravital two-photon microscopy. Myeloma cells are double-labelled with both fixed genetic reporters and lipophilic membrane dyes, which are retained by non-dividing myeloma cells. Intravital microscopy is used to resolve single tumour cells as they arrive in bone and engage in the bone niche, to track the transition from dormancy to active growth, and to follow the serial growth of tumour colonies by repeated imaging of the same mouse at weekly intervals. These studies show that myeloma cells can be held in a dormant state by osteoblast-like cells in the endosteal niche, and this state confers dormant cells with drug resistance. Furthermore, direct activation of osteoclasts can remodel the endosteal surface to release dormant myeloma cells from the niche and stochastically facilitate their reactivation to repopulate the tumour. Thus, myeloma cell dormancy is a reversible state controlled by the extrinsic bone microenvironment, which can be manipulated to change the course of the disease. RESULTS Colonizing myeloma cells engage in the endosteal niche C57BL/KaLwRijHsd mice were injected with syngeneic 5TGM1-enhanced green fluorescent protein (eGFP) murine myeloma cells and GFP+ cells arriving in the intact tibia were visualized in real time by intravital two-photon microscopy (Fig. 1a–c; Supplementary Movie 1). Rare colonizing myeloma cells were observed as they migrated from the marrow space towards endocortical bone surfaces, where they arrested (Fig. 1a–c). Histological analysis confirmed the presence of individual CD138+ cells adjacent to endosteal bone surfaces 1 and 3 days after tumour cell inoculation (Fig. 1d). The majority of myeloma cells continued to circulate through the bone marrow, where they were only briefly captured in the imaging volume as they flowed through in blood vessels (Fig. 1a–c; Supplementary Movie 2). These circulating cells were seen throughout the duration of the imaging period (>60 min), although the absolute numbers were likely underestimated, as images were captured at 30-s intervals (Fig. 1c). Nevertheless, real-time intravital